At a Glance
| Feature | Detail |
|---|---|
| Name / structure | PNC-27: 32-amino-acid chimeric peptide, p53 residues 12–26 (the HDM-2-binding domain) joined to the penetratin cell-penetrating sequence; PNC-28 is a shorter analogue (p53 residues 17–26) |
| Origin | SUNY Downstate Medical Center (Pincus, Michl, Sarafraz-Yazdi and colleagues); later work involves NomoCan Pharmaceuticals |
| Proposed mechanism | Binds HDM-2 on the outer membrane of tumour cells, forms transmembrane pores, causes necrosis (“poptosis”) |
| Studied in | Human tumour cell lines, patient-derived ovarian cancer tissue in the laboratory, mouse models (pancreatic tumour, acute myeloid leukaemia) |
| Route in research | Added to cell culture; given to mice by the investigators |
| Human dose | None established; no human trial |
| Evidence level | Limited: preclinical only; no published or registered human trial |
| Regulatory status | Not approved anywhere; FDA public warning (2017); WADA 2026: S0 (non-approved substance) |
PNC-27 is discussed online as if it were a treatment. It is not one. It is a laboratory research peptide with an interesting mechanism, a series of papers mostly from one research group, and no human clinical trial. I am writing this page because people search for it, often on behalf of someone they love, and they deserve a plain account of what was tested, in what model, and what remains unknown.
How it is proposed to work
The p53 protein is a tumour suppressor. Inside the cell, HDM-2 (the human version of MDM2) binds p53 and marks it for destruction. Residues 12–26 of p53 form the binding site for HDM-2. PNC-27 consists of this p53 segment fused to penetratin, a sequence that helps peptides cross membranes.
The research group’s central finding is that many tumour cell lines carry HDM-2 on their outer cell membrane, while the untransformed cells they tested did not [1]. In their experiments, PNC-27 bound this membrane HDM-2, and when untransformed cells were engineered to display HDM-2 on their surface, they became susceptible [1]. Electron microscopy showed pores in the membranes of treated pancreatic cancer cells, and the authors describe the peptide and HDM-2 forming complexes that assemble into transmembrane channels [4][5]. The cell then dies by necrosis rather than apoptosis, which the authors call “poptosis”.
This is a coherent mechanism in the laboratory. Whether membrane HDM-2 is present on tumours in patients, whether enough peptide reaches a tumour after it is given, and how normal tissues respond in a whole body have not been tested in humans.
What the evidence shows
Human studies
None. No clinical trial of PNC-27 has been published in a peer-reviewed journal, and searches of ClinicalTrials.gov for “PNC-27” or “PNC27” return no registered study. The only human report I found is a conference case abstract describing a woman with metastatic cervical cancer who developed massive upper gastrointestinal bleeding two days after a PNC-27 infusion given at a clinic abroad and later died; the authors state that causation is uncertain [9].
Laboratory and animal studies
| Study | Model | What was tested | Finding |
|---|---|---|---|
| Michl 2006 [2] | Nude mice with transplanted rat pancreatic tumour cells | PNC-28 (shorter analogue) given into the peritoneal cavity over 2 weeks | Destroyed co-implanted tumours; slowed growth of tumours at a remote site, which then regrew slowly |
| Sarafraz-Yazdi 2010 [1] | Human cancer and untransformed cell lines | Membrane HDM-2 expression and PNC-27 binding | Membrane HDM-2 in many cancer cell lines, not in the untransformed lines tested; PNC-27 bound it |
| Sarafraz-Yazdi 2015 [6] | Patient-derived ovarian cancer tissue, tested in the laboratory | Ex vivo exposure to PNC-27 | Cytotoxic to the tumour samples tested |
| Alagkiozidis 2017 [7] | Ovarian cancer cell lines | PNC-27 after paclitaxel | Investigated whether cells surviving paclitaxel were sensitive to PNC-27 |
| Wang 2020 [3] | Human and mouse AML cells; mouse transplant models | Membrane HDM-2 on leukaemia cells; PNC-27 in vivo | Killed AML blasts and leukaemia stem cells in mice and spared normal blood stem cell function in mouse transplant experiments |
| Sarafraz-Yazdi 2022 [4] | Pancreatic cancer cells | Membrane pore formation | Pores seen by electron microscopy; complete tumour-cell killing in culture above about 100 µg/mL |
The authors of several of these papers developed the peptide, and the 2022 and 2024 papers declare employment with a company working on it [4][5]. The work comes almost entirely from one research network and has not progressed into the formal preclinical programme that precedes human trials. The leukaemia paper from a separate US and Chinese group [3] is the main exception.
Dosing
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
No human dose exists, because no human study exists. The table lists what was used in which research model, and what has been reported outside research.
| Setting | Dose / concentration | Route | Frequency | Duration | Basis |
|---|---|---|---|---|---|
| Pancreatic cancer cells in culture | About 100–150 µg/mL | Added to culture medium | Single exposure | Minutes | Laboratory study [4] |
| Rat pancreatic tumour in nude mice (PNC-28) | Dose set by the investigators (see original paper) | Intraperitoneal | Continuous over 2 weeks | 2 weeks | Animal study [2] |
| Human and mouse AML in mouse transplant models | Dose set by the investigators (see original paper) | Given to mice | Per study protocol | Per study protocol | Animal study [3] |
| Products sold outside research | Injections, IV infusions, nebulised solutions and suppositories without a tested dose; online reports mention injections in the low hundreds of micrograms | Various | Various | Various | Anecdotal; not a protocol |
Doses from cell culture or mice do not translate into a human dose. Any number presented online as “the PNC-27 protocol” has no trial behind it.
What people report: what works and what doesn’t
Reported to work
- No verifiable report of benefit in a person turned up in my search. Online threads asking whether anyone has used it typically receive replies pointing out that there is no human evidence (r/pancreaticcancer).
Mixed or unclear
- Self-experiment threads describe use alongside standard treatment, which makes any change impossible to attribute (r/BiohackingU).
Reported problems
- In the same self-experiment thread: a large local allergic reaction after a dose increase, and a marked drop in white and red blood cell counts that delayed radiotherapy in one user. These are single anecdotes; causation is unknown.
- The fatal bleeding case after an infusion abroad [9].
- Contaminated products (see below).
What a proper programme would need to show before any statement about people is possible: formal toxicology, a phase 1 dose-finding study measuring safety and blood levels, and evidence that membrane HDM-2 is present on the tumours of the people being studied.
Safety and side effects
There are no human safety data. What is documented:
- Contamination. In January 2017 the FDA warned people not to use PNC-27 products after finding the bacterium Variovorax paradoxus in an inhaled PNC-27 solution; the products were sold online as nebulised, intravenous, vaginal and rectal forms (Pharmacy Times report).
- Criminal case. A US man pleaded guilty in 2021 to conspiracy to introduce adulterated and misbranded drugs into interstate commerce. According to the plea agreement, he bought PNC-27 from a manufacturer in China and made and sold PNC-27 products; the US Attorney’s office notes that PNC-27 is not FDA-approved for any disease and has not undergone clinical trials in the United States [10].
- Biological unknowns. HDM-2 and p53 pathways are active in normal tissues, penetratin-type sequences enter many cell types, and pore-forming agents can damage blood cells or vessel walls. None of this has been measured in people.
Anyone who has already taken or been offered PNC-27 should tell their treating oncologist, including the product source and route, because of possible interactions with ongoing treatment, the infection risk from non-sterile products and the bleeding report above.
Legal and regulatory status
- United States. Not approved. The FDA has publicly warned against PNC-27 products, and federal prosecutors have pursued a supplier (see above).
- EU and Germany. Not authorised. German law on advertising for medicines (HWG) restricts promotion of treatments for cancer to the public; this page describes research only.
- Sport. As a non-approved pharmacological substance, PNC-27 falls under WADA 2026 class S0 [8].
How it fits
PNC-27 sits with the peptides on this site that have striking laboratory data and no human trials, such as FOXO4-DRI. Mouse and cell data are where many drugs start and where most of them stop. The honest status of PNC-27 is that it never moved into the formal clinical development that would tell us whether it is safe or useful in people.
Related Articles
- FOXO4-DRI and Senolytic Peptides: Mouse Data, Zero Human Trials
- Are Peptides Legal? A 2026 Regulatory Guide
- Peptide Safety Overview
- Peptide Sourcing: Quality and Grey-Market Risks
Frequently asked questions
Has PNC-27 been tested in humans?
No clinical trial of PNC-27 in humans has been published, and none is registered on ClinicalTrials.gov. The published research consists of cell-culture studies, tissue samples tested in the laboratory and mouse experiments.
How is PNC-27 supposed to work?
It contains the part of the p53 protein that binds HDM-2 (MDM2), linked to a cell-penetrating sequence called penetratin. The researchers report that HDM-2 sits on the outer membrane of many tumour cell lines but not of the normal cells they tested, and that PNC-27 binding to it forms pores that make the cell burst.
Is PNC-27 approved anywhere?
No. It is not approved by the FDA, the EMA or any other regulator. In 2017 the FDA warned the public not to use PNC-27 products after finding bacteria in an inhaled product, and in 2021 a US man pleaded guilty to federal charges for making and selling PNC-27 products.
What dose of PNC-27 is used?
There is no established human dose because there are no human studies. Laboratory studies used concentrations around 100–150 micrograms per millilitre on cells. Products sold outside research have been offered as injections, nebulised solutions and suppositories without any tested dose.
References
- Sarafraz-Yazdi E, Bowne WB, Adler V, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci U S A. 2010. PMID: 20080680. https://pubmed.ncbi.nlm.nih.gov/20080680/
- Michl J, Scharf B, Schmidt A, et al. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer. 2006. PMID: 16688716. https://pubmed.ncbi.nlm.nih.gov/16688716/
- Wang H, Zhao D, Nguyen LX, et al. Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia. Leukemia. 2020. PMID: 31337857. https://pubmed.ncbi.nlm.nih.gov/31337857/
- Sarafraz-Yazdi E, Mumin S, Cheung D, et al. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomedicines. 2022. PMID: 35625682. https://pubmed.ncbi.nlm.nih.gov/35625682/
- Pincus MR, Silberstein M, Zohar N, et al. Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells. Biomedicines. 2024. PMID: 38927351. https://pubmed.ncbi.nlm.nih.gov/38927351/
- Sarafraz-Yazdi E, Gorelick C, Wagreich AR, et al. Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer. Ann Clin Lab Sci. 2015. PMID: 26663795. https://pubmed.ncbi.nlm.nih.gov/26663795/
- Alagkiozidis I, Gorelick C, Shah T, et al. Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer. Ann Clin Lab Sci. 2017. PMID: 28667027. https://pubmed.ncbi.nlm.nih.gov/28667027/
- World Anti-Doping Agency. The 2026 Prohibited List (S0), as published in Tractatenblad 2026, 25. https://zoek.officielebekendmakingen.nl/trb-2026-25.html
- Aguon et al. Experimental PNC-27 Therapy and Massive GI Hemorrhage. Am J Gastroenterol. 2017;112(Suppl) (conference abstract, not indexed in PubMed). https://journals.lww.com/ajg/fulltext/00000434-201710001-01880~experimental-pnc-27-therapy-and-massive-gi-hemorrhage-a
- U.S. Department of Justice, Northern District of Alabama. US v Bishop. https://www.justice.gov/usao-ndal/us-v-bishop
Disclaimer: This article describes laboratory research for information only. PNC-27 is not an approved medicine and has not been tested in human clinical trials. It is not a treatment option, and nothing here is medical advice.
